# Biotech Daily Digest â€” 2025-09-08

**35 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 8 items
- Fierce Biotech: 5 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 20 items


## Eli Lilly Press Releases

- **[Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naÃ¯ve CLL/SLL](https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-first-and-only-approved-non-0)**  
  _Mon, 08 Sep 2025 06:45:00 -0400_  
  In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine plus rituximab , indicating one of the most compelling effect sizes ever observed for a single


## Endpoints News

- **[BridgeBio's Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial](https://endpoints.news/bridgebios-phase-2-hypoparathyroidism-data-fda-clears-second-pig-kidney-trial/)**  
  _Mon, 08 Sep 2025 14:11:52 +0000_  
  Plus, news about Saol Therapeutics, Eisai, Takeda's Vonvendi, Junshi Biosciences, Belite Bio, Integra Therapeutics, Novonesis and Novo Nordisk:

 ðŸ“Š BridgeBioâ€™s positive hypoparathyroidism results: The biotechâ€™s encaleret normalized urine ...

- **[Rapport reveals promising open-label study data for epilepsy pill, heads to Phase 3](https://endpoints.news/rapport-reports-promising-open-label-study-data-for-epilepsy-pill-heads-to-phase-3/)**  
  _Mon, 08 Sep 2025 10:00:35 +0000_  
  Rapport Therapeutics' shares {$RAPP} jumped 170% at market open Monday after it posted topline mid-stage data indicating that its epilepsy pill can cut seizure frequency.

 However, the trial was small and ...

- **[#WCLC25: AstraZenecaâ€™s Tagrisso combo extends survival by 10 months in EGFR-mutant lung cancer](https://endpoints.news/wclc25-astrazenecas-tagrisso-combo-extends-survival-by-10-months-in-egfr-mutant-lung-cancer/)**  
  _Mon, 08 Sep 2025 08:22:44 +0000_  
  The combination of AstraZenecaâ€™s Tagrisso and chemotherapy cut the risk of death by 23% compared to Tagrisso alone for patients with advanced EGFR-mutant lung cancer.

 In the FLAURA2 study's key overall survival endpoint, patients who ...

- **[#WorldSleep2025: Alkermesâ€™ success in Phase 2 narcolepsy trial is clouded by side effects](https://endpoints.news/alkermes-success-in-phase-2-narcolepsy-trial-is-clouded-by-side-effects/)**  
  _Mon, 08 Sep 2025 07:15:52 +0000_  
  Alkermesâ€™ narcolepsy drug candidate alixorexton significantly improved how long patients can stay awake in a mid-stage trial, but a high rate of vision-related side effects could cause trouble for the treatment.

 Back in July, the ...

- **[#WorldSleep2025: Takedaâ€™s Phase 3 narcolepsy results could make it first mover in multibillion-dollar market](https://endpoints.news/takedas-phase-3-narcolepsy-results-could-make-it-first-mover-in-multibillion-dollar-market/)**  
  _Mon, 08 Sep 2025 07:15:19 +0000_  
  Takeda has shared detailed data from two Phase 3 trials of its orexin agonist in narcolepsy type 1, bringing the Japanese drugmaker a step closer to a market that Wall Street says could generate sales ...

- **[Servier buys Medicxi startup's fragile X candidate for up to $450M](https://endpoints.news/servier-buys-medicxi-startups-fragile-x-candidate-for-up-to-450m/)**  
  _Mon, 08 Sep 2025 06:30:05 +0000_  
  French pharma Servier will pay up to $450 million for an experimental fragile X syndrome drug from UK-based startup Kaerus Bioscience, the companies said Monday morning.

 The deal for KER-0193, an oral small molecule that ...

- **[China biotech Epigenic raises $60M to test CRISPR epigenetic therapies](https://endpoints.news/china-biotech-epigenic-raises-60m-to-test-crispr-epigenetic-therapies/)**  
  _Mon, 08 Sep 2025 02:00:04 +0000_  
  Epigenic Therapeutics has raised a $60 million Series B financing to ramp up clinical tests of what it hopes could be a cure for chronic hepatitis B, using a version of CRISPR gene editing that ...

- **[#WCLC25: Merck and Daiichi Sankyo head to FDA with ADC for small cell lung cancer](https://endpoints.news/wclc25-merck-and-daiichi-sankyo-head-to-fda-with-adc-for-small-cell-lung-cancer/)**  
  _Sun, 07 Sep 2025 21:31:10 +0000_  
  Nearly half of patients with an aggressive form of lung cancer saw their tumors shrink substantially after receiving an antibody-drug conjugate developed by Daiichi Sankyo and Merck, according to the results of a mid-stage trial ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/dianthus-gmg-prospect-blooms-phase-2-win-setting-pivotal-plans" hreflang="en">Dianthus' gMG prospect blooms, with phase 2 win setting up pivotal plans</a>](https://www.fiercebiotech.com/biotech/dianthus-gmg-prospect-blooms-phase-2-win-setting-pivotal-plans)**  
  _Sep 8, 2025 9:26am_  
  Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase study.

- **[<a href="https://www.fiercebiotech.com/biotech/atom-claims-phase-3-win-shows-gout-drug-can-beat-competition-efficacy-safety" hreflang="en">Atom claims phase 3 win shows gout drug can beat competition in efficacy, safety</a>](https://www.fiercebiotech.com/biotech/atom-claims-phase-3-win-shows-gout-drug-can-beat-competition-efficacy-safety)**  
  _Sep 8, 2025 8:38am_  
  Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition.

- **[<a href="https://www.fiercebiotech.com/biotech/rapports-seizure-drug-hits-phase-2-sending-stock-soaring" hreflang="en">Rapport's seizure drug hits in phase 2, sending stock soaring </a>](https://www.fiercebiotech.com/biotech/rapports-seizure-drug-hits-phase-2-sending-stock-soaring)**  
  _Sep 8, 2025 8:14am_  
  A phase 2a trial of Rapport Therapeuticsâ€™ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotechâ€‹â€‹ up more than 157% in premarket trading.

- **[<a href="https://www.fiercebiotech.com/biotech/junshi-heralds-phase-3-psoriasis-win-il-17-drug-prepares-push-chinese-regulators" hreflang="en">Junshi heralds phase 3 psoriasis win for IL-17 drug, prepares push to Chinese regulators</a>](https://www.fiercebiotech.com/biotech/junshi-heralds-phase-3-psoriasis-win-il-17-drug-prepares-push-chinese-regulators)**  
  _Sep 8, 2025 4:57am_  
  Junshi has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval.

- **[<a href="https://www.fiercebiotech.com/biotech/daiichi-mercks-advanced-lung-cancer-adc-sees-48-response-registrational-trial" hreflang="en">Daiichi-Merck's advanced lung cancer ADC sees 48% response rate in registrational trial</a>](https://www.fiercebiotech.com/biotech/daiichi-mercks-advanced-lung-cancer-adc-sees-48-response-registrational-trial)**  
  _Sep 5, 2025 12:01pm_  
  Partners Daiichi Sankyo and Merck & Co. are sharing phase 2 data for their investigational antibody-drug conjugate, findings the partners think will help score accelerated approval in pretreated small cell lung cancer.


## Regeneron Press Releases

- **[Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies](https://investor.regeneron.com/news-releases/news-release-details/regeneron-advances-allergy-pipeline-two-positive-phase-3-trials)**  
  _Mon, 08 Sep 2025 06:30:00 -0400_  
  In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support further Phase 3 development TARRYTOWN, N.Y. , Sept.


## arXiv q-bio

- **[Mechanisms for anesthesia, unawareness, respiratory depression, memory replay and sleep: MHb > IPN > PAG + DRN + MRN > claustrum > cortical slow-waves](https://arxiv.org/abs/2509.04454)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04454v1 Announce Type: new 
Abstract: My findings show, for the first time, what causes loss of awareness, anesthesia, memory replay, opioids induced respiratory depression (OIRD), and slow wave sleep. Opiates are fast pain relievers and anesthetics that can cause respiratory arrest. I found how mu-opioidsâ€¦

- **[Thermodynamic analysis of water sorption isotherms on magnetically treated maize (Zea mays L.) seeds](https://arxiv.org/abs/2509.04586)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04586v1 Announce Type: new 
Abstract: Magnetic seed treatment (MST) is an effective technique for improving conditions in processes associated with germination, stability, and, ultimately, crop production. In this work, the technical management parameters related to the water adsorption process on magneticaâ€¦

- **[Integrating upstream and downstream reciprocity stabilizes cooperator-defector coexistence in N-player giving games](https://arxiv.org/abs/2509.04743)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04743v1 Announce Type: new 
Abstract: Human cooperation persists among strangers despite theoretical predictions of difficulties in large, well-mixed populations, leaving a fundamental evolutionary puzzle. While upstream (pay-it-forward: helping others because you were helped) and downstream (rewarding-repuâ€¦

- **[The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors](https://arxiv.org/abs/2509.04939)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04939v1 Announce Type: new 
Abstract: Background: Many advanced cancer patients experience progression under immune-checkpoint inhibitors (ICIs). Circulating cell-free DNA (cfDNA) size profiles offer a promising noninvasive multi-cancer approach to monitor and predict immunotherapy response. Methods: In theâ€¦

- **[Revealing the building blocks of tree balance: fundamental units of the Sackin and Colless Indices](https://arxiv.org/abs/2509.04995)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04995v1 Announce Type: new 
Abstract: Over the past decades, more than 25 phylogenetic tree balance indices and several families of such indices have been proposed in the literature -- some of which even contain infinitely many members. It is well established that different indices have different strengthsâ€¦

- **[Network Models of Neurodegeneration: Bridging Neuronal Dynamics and Disease Progression](https://arxiv.org/abs/2509.05151)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.05151v1 Announce Type: new 
Abstract: Neurodegenerative diseases are characterized by the accumulation of misfolded proteins and widespread disruptions in brain function. Computational modeling has advanced our understanding of these processes, but efforts have traditionally focused on either neuronal dynamâ€¦

- **[Resolving Tangling in Multi-Conformer Refinement via Iterative Projections](https://arxiv.org/abs/2509.05189)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.05189v1 Announce Type: new 
Abstract: The advent of advanced crystallographic techniques has shifted structural biology from static, single-conformer models toward probing protein dynamics. Extracting cooperative motions from temporally and spatially averaged electron density maps requires both high-resolutâ€¦

- **[Scaling Environments for Organoid Intelligence with LLM-Automated Design and Plasticity-Based Evaluation](https://arxiv.org/abs/2509.04633)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04633v1 Announce Type: cross 
Abstract: As the complexity of artificial agents increases, the design of environments that can effectively shape their behavior and capabilities has become a critical research frontier. We propose a framework that extends this principle to a novel class of agents: biological nâ€¦

- **[When correcting for regression to the mean is worse than no correction at all](https://arxiv.org/abs/2509.04718)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04718v1 Announce Type: cross 
Abstract: The ubiquitous regression to the mean (RTM) effect complicates statistical inference in biological studies of change. We demonstrate that common RTM correction methods are flawed: the Berry et al. method popularized by Kelly & Price in The American Naturalist is unrelâ€¦

- **[Pose-Free 3D Quantitative Phase Imaging of Flowing Cellular Populations](https://arxiv.org/abs/2509.04848)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04848v1 Announce Type: cross 
Abstract: High-throughput 3D quantitative phase imaging (QPI) in flow cytometry enables label-free, volumetric characterization of individual cells by reconstructing their refractive index (RI) distributions from multiple viewing angles during flow through microfluidic channelsâ€¦

- **[Determining a parabolic-elliptic-elliptic system by boundary observation of its non-negative solutions under chemotaxis background](https://arxiv.org/abs/2509.04850)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04850v1 Announce Type: cross 
Abstract: This paper addresses a profoundly challenging inverse problem that has remained largely unexplored due to its mathematical complexity: the unique identification of all unknown coefficients in a coupled nonlinear system of mixed parabolic-elliptic-elliptic type using oâ€¦

- **[Directed Evolution of Proteins via Bayesian Optimization in Embedding Space](https://arxiv.org/abs/2509.04998)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04998v1 Announce Type: cross 
Abstract: Directed evolution is an iterative laboratory process of designing proteins with improved function by iteratively synthesizing new protein variants and evaluating their desired property with expensive and time-consuming biochemical screening. Machine learning methodsâ€¦

- **[Dynamical Learning in Deep Asymmetric Recurrent Neural Networks](https://arxiv.org/abs/2509.05041)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.05041v1 Announce Type: cross 
Abstract: We show that asymmetric deep recurrent neural networks, enhanced with additional sparse excitatory couplings, give rise to an exponentially large, dense accessible manifold of internal representations which can be found by different algorithms, including simple iteratâ€¦

- **[Elasticity and plasticity of epithelial gap closure](https://arxiv.org/abs/2509.05110)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.05110v1 Announce Type: cross 
Abstract: Epiboly, during which a tissue closes around the surface of the egg, pervades animal development. This epithelial gap closure involves cell intercalations at the edge of the gap. Here, inspired by serosa closure in the beetle Tribolium, we study the interplay betweenâ€¦

- **[Stochastic synaptic dynamics under learning](https://arxiv.org/abs/2508.13846)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2508.13846v2 Announce Type: replace 
Abstract: Learning is based on synaptic plasticity, which affects and is driven by neural activity. Because pre- and postsynaptic spiking activity is shaped by randomness, the synaptic weights follow a stochastic process, requiring a probabilistic framework to capture the noiâ€¦

- **[Net2Brain: A Toolbox to compare artificial vision models with human brain responses](https://arxiv.org/abs/2208.09677)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2208.09677v4 Announce Type: replace-cross 
Abstract: We introduce Net2Brain, a graphical and command-line user interface toolbox for comparing the representational spaces of artificial deep neural networks (DNNs) and human brain recordings. While different toolboxes facilitate only single functionalities or onlyâ€¦

- **[The dynamic interplay between in-context and in-weight learning in humans and neural networks](https://arxiv.org/abs/2402.08674)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2402.08674v5 Announce Type: replace-cross 
Abstract: Human learning embodies a striking duality: sometimes, we appear capable of following logical, compositional rules and benefit from structured curricula (e.g., in formal education), while other times, we rely on an incremental approach or trial-and-error, learâ€¦

- **[Assumption-Lean Post-Integrated Inference with Surrogate Control Outcomes](https://arxiv.org/abs/2410.04996)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2410.04996v3 Announce Type: replace-cross 
Abstract: Data integration methods aim to extract low-dimensional embeddings from high-dimensional outcomes to remove unwanted variations, such as batch effects and unmeasured covariates, across heterogeneous datasets. However, multiple hypothesis testing after integratâ€¦

- **[Histo-Miner: Deep Learning based Tissue Features Extraction Pipeline from H&E Whole Slide Images of Cutaneous Squamous Cell Carcinoma](https://arxiv.org/abs/2505.04672)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2505.04672v2 Announce Type: replace-cross 
Abstract: Recent advancements in digital pathology have enabled comprehensive analysis of Whole-Slide Images (WSI) from tissue samples, leveraging high-resolution microscopy and computational capabilities. Despite this progress, there is a lack of labeled datasets and oâ€¦

- **[Nanometer-precision tracking of adipocyte dynamics via single lipid droplet whispering-gallery optical resonances](https://arxiv.org/abs/2509.04201)**  
  _Mon, 08 Sep 2025 00:00:00 -0400_  
  arXiv:2509.04201v2 Announce Type: replace-cross 
Abstract: Biophotonics-and more recently, biointegrated photonics-offer transformative tools for probing cellular processes with unprecedented precision. Among these, whispering gallery mode (WGM) resonators-optical microcavities formed in spherical structures-have emerâ€¦
